Antenatal visits are positively associated with uptake of tetanus toxoid and intermittent preventive treatment in pregnancy in Ivory Coast.


Journal

BMC public health
ISSN: 1471-2458
Titre abrégé: BMC Public Health
Pays: England
ID NLM: 100968562

Informations de publication

Date de publication:
06 Nov 2019
Historique:
received: 13 04 2019
accepted: 25 10 2019
entrez: 8 11 2019
pubmed: 7 11 2019
medline: 29 1 2020
Statut: epublish

Résumé

Malaria and tetanus infections among pregnant women represent two major public health problems in sub-Saharan Africa. Optimum use of Intermittent preventive treatment in pregnancy (IPTp) with sulfadoxine-pyrimethamine (IPTp-SP) and immunization against tetanus among pregnant women during antenatal care (ANC) visits are recommended strategies to prevent these issues. Despite these recommendations, many women in Africa remain deprived of these cost-effective and life-saving interventions. In this study, we aimed to examine the prevalence of women using these two services, and the association between women's uptake of IPTp-SP and tetanus toxoid (TT) with antenatal care use in Ivory Coast. This study was based on the fifth round of Multiple Indicator Cluster Survey (MICS 5) conducted in Ivory Coast in 2016. Participants were 9583 women aged between 15 and 49 years. Outcomes were TT and Intermittent preventive treatment with sulfadoxine-pyrimethamine (IPTp-SP). Data analysis was conducted using bivariate and multiple logistic regression. In this study, the prevalence of taking TT immunization and IPTp-SP drugs was 81.97 and 17.83% respectively. Of the participants who took these drugs at all, the prevalence of taking adequate doses of TT immunization was 78.75% and that of IPTp-SP was 35.46%. In the multivariable analysis model, higher age groups, 25-29 years (OR = 2.028, 95%CI = 1.120-3.669) were found to be positively associated with uptake of adequate doses of IPTp-SP drugs. Women who attended at least four ANC visits had higher odds of taking IPTp-SP drugs (OR = 1.656, 95%CI = 1.194-2.299) and TT immunization (OR = 2.347, 95%CI = 1.384-3.981), and also had higher odds of receiving adequate doses of IPTp-SP drugs (OR = 3.291, 95%CI = 2.157-5.020) and that of TT immunization (OR = 1.968, 95%CI = 1.398-2.771). The odds of taking IPTp-SP drugs were significantly higher among women with primary (OR = 2.504, 95%CI = 1.020-6.146) and secondary/higher education (OR = 3.298, 95%CI = 1.343-8.097) compared to those with no education. Also, women with higher parity had lower odds of taking TT immunization (OR = 0.218, 95%CI = 0.055-0.858) compared to those with lower parity. Findings from this study also revealed that the odds of taking adequate doses of IPTp-SP drugs were significantly lower among participants from Mandé du Nord ethnicity (OR = 0.378,95%CI = 0.145-0.983) compared to those from other ethnicities. In this study, uptake of IPTp-SP drugs was much lower than TT immunization. High number of ANC visits were found to be significantly associated with taking IPTp-SP drugs and TT immunization and also with that of taking them in adequate doses. Vaccination promotion is necessary to protect pregnant women and reduce adverse health outcomes among the newborn in Ivory Coast.

Sections du résumé

BACKGROUND BACKGROUND
Malaria and tetanus infections among pregnant women represent two major public health problems in sub-Saharan Africa. Optimum use of Intermittent preventive treatment in pregnancy (IPTp) with sulfadoxine-pyrimethamine (IPTp-SP) and immunization against tetanus among pregnant women during antenatal care (ANC) visits are recommended strategies to prevent these issues. Despite these recommendations, many women in Africa remain deprived of these cost-effective and life-saving interventions. In this study, we aimed to examine the prevalence of women using these two services, and the association between women's uptake of IPTp-SP and tetanus toxoid (TT) with antenatal care use in Ivory Coast.
METHODS METHODS
This study was based on the fifth round of Multiple Indicator Cluster Survey (MICS 5) conducted in Ivory Coast in 2016. Participants were 9583 women aged between 15 and 49 years. Outcomes were TT and Intermittent preventive treatment with sulfadoxine-pyrimethamine (IPTp-SP). Data analysis was conducted using bivariate and multiple logistic regression.
RESULTS RESULTS
In this study, the prevalence of taking TT immunization and IPTp-SP drugs was 81.97 and 17.83% respectively. Of the participants who took these drugs at all, the prevalence of taking adequate doses of TT immunization was 78.75% and that of IPTp-SP was 35.46%. In the multivariable analysis model, higher age groups, 25-29 years (OR = 2.028, 95%CI = 1.120-3.669) were found to be positively associated with uptake of adequate doses of IPTp-SP drugs. Women who attended at least four ANC visits had higher odds of taking IPTp-SP drugs (OR = 1.656, 95%CI = 1.194-2.299) and TT immunization (OR = 2.347, 95%CI = 1.384-3.981), and also had higher odds of receiving adequate doses of IPTp-SP drugs (OR = 3.291, 95%CI = 2.157-5.020) and that of TT immunization (OR = 1.968, 95%CI = 1.398-2.771). The odds of taking IPTp-SP drugs were significantly higher among women with primary (OR = 2.504, 95%CI = 1.020-6.146) and secondary/higher education (OR = 3.298, 95%CI = 1.343-8.097) compared to those with no education. Also, women with higher parity had lower odds of taking TT immunization (OR = 0.218, 95%CI = 0.055-0.858) compared to those with lower parity. Findings from this study also revealed that the odds of taking adequate doses of IPTp-SP drugs were significantly lower among participants from Mandé du Nord ethnicity (OR = 0.378,95%CI = 0.145-0.983) compared to those from other ethnicities.
CONCLUSION CONCLUSIONS
In this study, uptake of IPTp-SP drugs was much lower than TT immunization. High number of ANC visits were found to be significantly associated with taking IPTp-SP drugs and TT immunization and also with that of taking them in adequate doses. Vaccination promotion is necessary to protect pregnant women and reduce adverse health outcomes among the newborn in Ivory Coast.

Identifiants

pubmed: 31694607
doi: 10.1186/s12889-019-7847-1
pii: 10.1186/s12889-019-7847-1
pmc: PMC6836543
doi:

Substances chimiques

Antimalarials 0
Drug Combinations 0
Tetanus Toxoid 0
fanasil, pyrimethamine drug combination 37338-39-9
Sulfadoxine 88463U4SM5
Pyrimethamine Z3614QOX8W

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1467

Références

J Nutr Metab. 2018 Nov 22;2018:2839579
pubmed: 30595915
BMC Pregnancy Childbirth. 2018 Apr 20;18(1):108
pubmed: 29678150
Oncotarget. 2016 Sep 27;7(39):62898-62911
pubmed: 27588486
Am J Public Health. 2003 Dec;93(12):2074-8
pubmed: 14652337
Mediterr J Hematol Infect Dis. 2012;4(1):e2012013
pubmed: 22550559
Hum Vaccin Immunother. 2019;15(2):283-286
pubmed: 30252609
Vaccine. 2018 Jun 14;36(25):3573-3575
pubmed: 28427847
Public Health. 2001 Sep;115(5):359-64
pubmed: 11593447
Trop Med Infect Dis. 2018 Feb 11;3(1):null
pubmed: 30274416
Lancet Infect Dis. 2007 Feb;7(2):93-104
pubmed: 17251080
J Community Health. 2013 Jun;38(3):492-9
pubmed: 23161213
Lancet Glob Health. 2017 Jan;5(1):e96-e103
pubmed: 27894851
Am J Trop Med Hyg. 2011 Jul;85(1):12-21
pubmed: 21734118
Cochrane Database Syst Rev. 2014 Oct 10;(10):CD000169
pubmed: 25300703
PLoS One. 2017 Nov 1;12(11):e0187090
pubmed: 29091923
Malar J. 2018 May 25;17(1):211
pubmed: 29793482
PLoS Negl Trop Dis. 2018 Aug 30;12(8):e0006667
pubmed: 30161119
PLoS One. 2010 Nov 29;5(11):e15066
pubmed: 21124732
Malar J. 2018 Oct 16;17(1):364
pubmed: 30326904
Lancet. 2015 Jan 31;385(9966):430-40
pubmed: 25280870
PLoS One. 2015 Sep 01;10(9):e0132562
pubmed: 26325522
Malar J. 2014 Nov 24;13:455
pubmed: 25421496
Trop Med Int Health. 2004 Jan;9(1):77-82
pubmed: 14728610
J Ayub Med Coll Abbottabad. 2010 Jul-Sep;22(3):136-40
pubmed: 22338439
Am J Trop Med Hyg. 2013 May;88(5):855-61
pubmed: 23458956
Afr Health Sci. 2015 Dec;15(4):1087-96
pubmed: 26958008
Lancet. 2007 Dec 8;370(9603):1947-59
pubmed: 17854885
Lancet. 2015 Jan 24;385(9965):362-70
pubmed: 25149223
Malar J. 2017 Aug 10;16(1):323
pubmed: 28797296
BMC Int Health Hum Rights. 2018 Jun 28;18(1):27
pubmed: 29950171
Int J Womens Health. 2015 Feb 03;7:171-80
pubmed: 25678822
Parasit Vectors. 2018 Jan 30;11(1):71
pubmed: 29382388
Parasit Vectors. 2014 Nov 20;7:495
pubmed: 25410760
Contemp Clin Trials Commun. 2017 Sep;7:57-63
pubmed: 29226266
Obes Sci Pract. 2017 Mar 27;3(2):185-192
pubmed: 28706731
Trop Med Infect Dis. 2019 Feb 07;4(1):null
pubmed: 30736456
Arch Public Health. 2016 Feb 01;74:5
pubmed: 26835009
BMC Public Health. 2015 Jun 07;15:540
pubmed: 26049737
Malar J. 2014 Jan 14;13:22
pubmed: 24423279
BMC Res Notes. 2016 Jun 21;9:318
pubmed: 27328717
Am J Public Health. 2011 Feb;101(2):285-93
pubmed: 21164098
PLoS One. 2012;7(8):e42857
pubmed: 22880123
J Health Popul Nutr. 2013 Jun;31(2):243-51
pubmed: 23930343
J Trop Med. 2018 Dec 4;2018:5019215
pubmed: 30631370
Therapie. 2019 Sep;74(4):487-494
pubmed: 30904318
Malar J. 2007 Nov 08;6:144
pubmed: 17996048
Lancet. 2016 Oct 8;388(10053):1725-1774
pubmed: 27733285
Lancet Infect Dis. 2005 Nov;5(11):695-708
pubmed: 16253887
Lancet Glob Health. 2015 Oct;3(10):e617-28
pubmed: 26296450
Pan Afr Med J. 2017 Oct 10;28:122
pubmed: 29515740
Bull World Health Organ. 1984;62(4):647-69
pubmed: 6386211
Hum Vaccin Immunother. 2013 Aug;9(8):1763-73
pubmed: 23584253
BMC Pregnancy Childbirth. 2018 Jun 15;18(1):235
pubmed: 29907139
Am J Trop Med Hyg. 2001 Jan-Feb;64(1-2 Suppl):28-35
pubmed: 11425175
BMC Pregnancy Childbirth. 2019 Oct 15;19(1):354
pubmed: 31615454
BMC Pregnancy Childbirth. 2018 Jun 7;18(1):216
pubmed: 29879939
PLoS One. 2014 Mar 20;9(3):e92102
pubmed: 24651078
Glob Health Res Policy. 2019 Mar 29;4:9
pubmed: 30976661
Ecohealth. 2010 Dec;7(4):507-16
pubmed: 20694503
Vaccine. 2015 Jun 12;33(26):2971-7
pubmed: 25936666

Auteurs

Sanni Yaya (S)

School of International Development and Global Studies, Faculty of Social Sciences, University of Ottawa, 120, University Private, Ottawa, ON, Ottawa, ON, K1N 6N5, Canada. sanni.yaya@uottawa.ca.
The George Institute for Global Health, The University of Oxford, Oxford, UK. sanni.yaya@uottawa.ca.

Komlan Kota (K)

Interdisciplinary School of Health Sciences, Faculty of Health Sciences, University of Ottawa, Ottawa, Canada.

Amos Buh (A)

Interdisciplinary School of Health Sciences, Faculty of Health Sciences, University of Ottawa, Ottawa, Canada.

Ghose Bishwajit (G)

School of International Development and Global Studies, Faculty of Social Sciences, University of Ottawa, 120, University Private, Ottawa, ON, Ottawa, ON, K1N 6N5, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH